For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Nuvectis Pharma Inc (NASDAQ: NVCT) closed at $7.86 down -2.72% from its previous closing price of $8.08. In other words, the price has decreased by -$2.72 from its previous closing price. On the day, 1.73 million shares were traded. NVCT stock price reached its highest trading level at $8.24 during the session, while it also had its lowest trading level at $7.7.
Ratios:
For a deeper understanding of Nuvectis Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.28. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on April 02, 2025, initiated with a Buy rating and assigned the stock a target price of $17.
On March 17, 2025, Laidlaw started tracking the stock assigning a Buy rating and target price of $19.
On July 13, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $21.Ladenburg Thalmann initiated its Buy rating on July 13, 2022, with a $21 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 20 ’25 when Mosseri Marlio Charles bought 5,603 shares for $7.99 per share. The transaction valued at 44,768 led to the insider holds 2,981,806 shares of the business.
Mosseri Marlio Charles bought 28,043 shares of NVCT for $225,746 on Jun 18 ’25. The 10% Owner now owns 2,976,203 shares after completing the transaction at $8.05 per share. On Jun 17 ’25, another insider, Mosseri Marlio Charles, who serves as the 10% Owner of the company, bought 5,399 shares for $8.11 each. As a result, the insider paid 43,786 and bolstered with 2,948,160 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCT now has a Market Capitalization of 164222912 and an Enterprise Value of 155903840.
Stock Price History:
The Beta on a monthly basis for NVCT is -0.26, which has changed by 0.18731117 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, NVCT has reached a high of $11.80, while it has fallen to a 52-week low of $4.44. The 50-Day Moving Average of the stock is -8.37%, while the 200-Day Moving Average is calculated to be 4.20%.
Shares Statistics:
For the past three months, NVCT has traded an average of 149.97K shares per day and 250080 over the past ten days. A total of 23.63M shares are outstanding, with a floating share count of 11.36M. Insiders hold about 45.63% of the company’s shares, while institutions hold 9.84% stake in the company. Shares short for NVCT as of 1751241600 were 2640426 with a Short Ratio of 17.61, compared to 1748563200 on 2109698. Therefore, it implies a Short% of Shares Outstanding of 2640426 and a Short% of Float of 24.440001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
